SEC Filing Summary: Ginkgo Bioworks Holdings, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ginkgo Bioworks Holdings, Inc. on August 7, 2025. The filing serves to announce the company's financial results for the second quarter ended June 30, 2025. The company is incorporated in Delaware and its Class A common stock trades on the NYSE under the symbol "DNA."
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results have been issued via a press release, which is attached as Exhibit 99.1, but the text of the press release itself is not included in the input data.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. It only references the issuance of the Q2 2025 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1), which is not part of the provided text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific Q2 2025 financial figures.
- Verify the company's cash position and burn rate given the absence of liquidity data in this summary.
- Check for any updated revenue guidance or operational milestones mentioned in the full press release.
- Confirm the status of any debt covenants or liquidity facilities referenced in the full financial statements.